Ondine Biomedical Inc
LSE:OBI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ondine Biomedical Inc
Operating Income
Ondine Biomedical Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Operating Income
-CA$19.4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Profound Medical Corp
TSX:PRN
|
Operating Income
-$41.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-17%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Operating Income
-CA$4.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
2%
|
|
|
MedMira Inc
XTSX:MIR
|
Operating Income
-CA$2.4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
1%
|
|
|
Aurora Spine Corp
XTSX:ASG
|
Operating Income
-$931.8k
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
Operating Income
-$20.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
What is Ondine Biomedical Inc's Operating Income?
Operating Income
-19.4m
CAD
Based on the financial report for Dec 31, 2024, Ondine Biomedical Inc's Operating Income amounts to -19.4m CAD.
What is Ondine Biomedical Inc's Operating Income growth rate?
Operating Income CAGR 3Y
-4%
Over the last year, the Operating Income growth was -31%. The average annual Operating Income growth rates for Ondine Biomedical Inc have been -4% over the past three years .
